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Abstract.12
Background: The risk of developing Alzheimer’s disease as well as its progression and severity are known to be different in
men and women, and cognitive decline is greater in women than in men at the same stage of disease and could be correlated








Methods: In this study we used transgenic mice expressing the wild-type human tau (hTau) which were subjected to
intraventricular (ICV) injections of A peptides in nanomolar concentration.
18
19
Results: We found that A42 produces pathological conformational changes and hyperphosphorylation of tau protein in
male or ovariectomized female mice but not in control females. The treatment of ovariectomized females with estradiol
replacement protects against the pathological conformation of tau and seems to be mediated by antioxidant activity as well





Conclusion: Our study indicates that factors as age, reproductive stage, hormone levels, and the interplay with other risk
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INTRODUCTION28
Hallmarks of Alzheimer’s disease (AD) are the29
accumulation of amyloid- (A) peptides in amy-30
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loid plaques, and the aggregation of tau protein to 31
form neurofibrillary tangles. 32
A derives from the amyloid- protein precur- 33
sor (APP) through  site APP cleaving enzyme 34
(BACE) 1 and -secretase processing that gener- 35
ates multiple C-termini, most ending at residue 40 36
and 42. A42 aggregates more quickly and sta- 37
bly than A40 through sequential phases: first A 38
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monomers aggregate into soluble oligomers that39
then form insoluble oligomers, generating protofib-40
rils and fibrils [1]. Recent studies indicate that41
plaques are not toxic but rather a reservoir of A42
molecules: small soluble oligomers are the key to43
A toxicity and in contrast, monomers have been44
suggested to be involved in physiological processes45
[2, 3].46
Several data support the amyloid hypothesis: accu-47
mulation of A peptides is the primary and early48
event that induces neuronal degeneration, character-49
ized by conformational altered aggregated tau. We50
have developed a powerful system based on male51
mice expressing the wild-type human tau (hTau)52
which were subjected to intraventricular (ICV) injec-53
tions of A peptides in nanomolar concentration. We54
discovered that A42 monomers, but not oligomers:55
1) produce paired helical filament-like conformation56
of tau protein, and 2) induce two phosphorylated epi-57
topes which are not present in normal tau (Ser396 and58
Ser422) through the activation of GSK3, JNK, and59
ERK 1/2 kinases [4].60
Recent epidemiological studies showed that two-61
thirds of AD patients are women [5], and this62
fact cannot be attributed only to their higher life63
expectancy. In this connection, the loss of estradiol64
might be one of the factors leading to declining cog-65
nitive function in women [6].66
Of note, we found that oxidative stress, together67
with important oxidative stress-related risk factors68
related to AD, such as hypoxia, hyperglycemia,69
and hypercholesterolemia, are potential causes of70
the increased BACE1 activity [7]. In AD, estro-71
gen neuroprotective activity is exerted at multiple72
levels. Preclinical data showed that, in addition to73
their action against neuroinflammation and oxida-74
tive stress, estrogens are able to influence both the75
main players of neurodegeneration, A, and tau76
[8].77
In this paper, we pursue the hypothesis that bio-78
logical sex influences the effect of A42 monomers79
on pathological tau conformational change. Our80
data revealed that A42 monomers produce the81
pathological conformational changes and hyperphos-82
phorylation of tau protein in male or ovariectomized83
female mice but not in control female. The treatment84
of ovariectomized females with estradiol replacement85
protects against the pathological conformation of tau.86
The hypothesized protective mechanism is mediated87
both by their antioxidant activity and by their ability88
to modulate the expression of miRNA 218 linked to89
tau phosphorylation.90
MATERIALS AND METHODS 91
Mice and ICV 92
hTau mice (Mapttm1(EGFP)KltTg(MAPT) 8cPdav/J; 93
#004808, Jackson Laboratory) were crossed with 94
tau knock-out (KO) mice (Mapttm1(EGFP)Klt/J; 95
#004779, Jackson Laboratory), to obtain preg- 96
nant females carrying hTau features as described 97
by Andorfer and colleagues, 2003 [9]. Mice 98
were genotyped by PCR assay using the fol- 99
lowing primers: human tau transgene (forward 100
5’-ACTTTGAACCAGGATGGCTGAGCCC-3’, 101
reverse 5’-CTGTGCATGGCTGTCCCTACCTT- 102
3’), mouse tau gene (forward 5’-CTCAGCAT 103
CCCACCTGTAAC-3’, reverse 5’-CCAGTTGT 104
GTATGTCCACCC-3’), and disrupted tau gene 105
(forward 5’-CAGGCTTTGAACCAGTATGG-3’, 106
reverse 5’-TGAACTTGTGGC CGTTTACG- 107
3’). Mice were maintained on a Swiss Webster/ 108
129/SvJae/C57BL/6 background [9]. Animals 109
were kept on a 12 h light/dark cycle with food 110
and water available ad libitum. All experimental 111
procedures on live animals were performed under 112
the supervision of a licensed veterinarian, according 113
to: 1) European Communities Council Directive 114
(November 24, 1986; 86/609/EEC), 2) Italian 115
Ministry of Health and University of Torino’s insti- 116
tutional guidelines on animal welfare (DL 116/92 117
on Care and Protection of living animals undergoing 118
experimental or other scientific procedures; autho- 119
rization No. 17/2010-B, June 30, 2010), and 3) ad 120
hoc Ethical Committee of the University of Turin 121
(http://www.unito.it/unitoWAR/page/istituzionale/ 122
ricerca1/Ricerca comitato1). 123
Two groups of 2-month-old male and/or female 124
mice were treated for 3 h (n = 60). Under isoflurane 125
O2/N2O anesthesia, hTau mice (n = 80) were ICV 126
injected with A peptides or saline. Coordinates 127
used for injection were: anteroposterior, –0.5 mm; 128
lateral, 1.2 mm relative to Bregma and dorsoven- 129
tral, 1.7 mm from the dural surface. The method was 130
validated by injecting one mouse with Trypan blue 131
(1 l). 132
Ovariectomy 133
Two groups of 2-month-old female mice under- 134
went bilateral ovariectomy (OVX) except for the 135
sham-operated groups. The bilateral ovaries of anaes- 136
thetized female mice were exposed through a midline 137
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ligating the uterine horn, the bilateral ovaries were139
removed. In the sham group, mice underwent the140
procedures of anesthesia, incisions, bilateral ovaries141
exposure and incision closure without bilateral142
ovaries removing. After the surgery procedure, OVX143
female mice were fed with phytoestrogen-free feed.144
Treatments145
Mice were injected with 0.2 M A42 peptides146
(#20276, Anaspec). The lyophilized synthetic pep-147
tides were dissolved in 1% of NH4OH to get a clear148
solution and stored at –20◦C in aliquots. Monomeric149
preparations were brought to 0.2 M (final con-150
centration) with sterile double distilled water,151
centrifuged at 10000 g for 10 min to remove possi-152
bly aggregates and then intraventricularly injected.153
The quality of A preparations was controlled using154
atomic force microscopy (AFM). AFM was car-155
ried out on a Multimode AFM with a Nanoscope156
V system operating in Tapping Mode using stan-157
dard antimony(n)-doped Si probes (T: 3.5–4.5 mm,158
L: 115–135 mm, W: 30–40 mm, f0:313–370 kHz, k:159
20–80 N/m) (Bruker). The scan rate was tuned pro-160
portionally to the area scanned and was kept in the161
0.5–1.2 Hz range. The sample was then diluted to162
5 M with PBS, and 50 l of solution was spot-163
ted onto a freshly cleaved muscovite mica disk and164
incubated for 5 min. The disk was then washed with165
ddH2O and dried under a gentle nitrogen stream.166
Samples were analyzed with the Scanning Probe167
Image Processor (SPIP Version 5.1.6 released April168
13, 2011) data analysis package (Nanoscience Instru-169
ments, Phoenix, AZ, USA). SPIP software was used170
to analyze the distribution of the molecular assem-171
blies of the different populations in terms of height172
and diameter, as previously described [10]. Our con-173
trols were hTau mice ICV injected with saline. The174
experiments were done four weeks after ovariec-175
tomy. After two weeks from ovariectomy surgery, one176
group of female mice was subjected to a daily sub-177
cutaneous injection of 17-estradiol (E2) for three178
weeks (1 g/Kg) [11]. Animals were allowed to179
recover for at least three weeks before experiments180
were performed and subsequently were subjected to181
intracerebroventricular injection of A42 monomers182
(200 nM) or saline and sacrificed after 3 h.183
Antibodies and immunoblot analysis184
Immunoblot analysis was performed using the185
following antibodies: MC1 (kind gift from Dr.186
P Davies, Albert Einstein College of Medicine, 187
New York, 1:500); Tau5 (Millipore, #577801, 188
1:500); AT8 (Innogenetics, #90206, 1:500); Tau 46 189
(Abcam, #22261, 1:1000), TaupS396 (Invitrogen, 190
#44752G, 1:1000); TaupS244 (Invitrogen, #44764G, 191
1:1000); GSK3/ tot (1:1000, Invitrogen, #44610, 192
1:1000); GSK3pS9 (Novex, #710100, 1:1000); 193
pJNK1/2 (Cell Signaling Technology, #9251, 1:500); 194
JNK1/2 (Cell Signaling Technology, #9252, 1:500); 195
pERK1/2 (Cell Signaling Technology, #43765, 196
1:1000); ERK1/2 (Santa Cruz Biotechnology, Sc-93, 197
1:1000; -actin (Sigma Aldrich). 198
Fresh frozen brains were mechanically homoge- 199
nized in ice-cold buffer (25 mM Tris-HCl pH 7.4, 200
150 mM NaCl, 1 mM EGTA, 1 mM EDTA, 1 mM 201
PMSF, phosphatase and protease inhibitors) and 202
then centrifuged at 10,000 g for 15 min at 4◦C 203
to isolate soluble proteins. Supernatants (2 mg/ml 204
solution) were collected and incubated with deter- 205
gent sarkosyl (5% final concentration) overnight at 206
4◦C. The sarkosyl mixtures were then centrifuged 207
in Beckman SW 55 Ti rotor at 35,000 rpm for 208
1 h at 4◦C. Pellets were resuspended in 100 l 209
sample buffer to obtain sarkosyl-insoluble proteins. 210
Lysates (20 g) were run on 3–8% Tris-HCl gra- 211
dient PAGE gel (Invitrogen) and then transferred 212
to nitrocellulose membrane. Blots were blocked 213
(5% no fat milk) and incubated overnight at 4◦C 214
with primary antibodies. Peroxidase-conjugated sec- 215
ondary antibodies were incubated 1 h at room 216
temperature (RT) and developed with Luminata 217
Forte Western substrate (WBLUF0100, Milli- 218
pore). Densitometric values were normalized to 219
-actin. 220
Total antioxidant capacity 221
To evaluate the antioxidant capacity of mice brain 222
tissues, we performed the total antioxidant capacity 223
(TAC) dosage kit (ab65329, Abcam). The analysis 224
was performed on total extracts according to the man- 225
ufacturing protocol. 226
Quantitative determination of 17β-estradiol 227
To quantify E2 levels, blood mice was collected to 228
obtain plasma. To perform the measuring, we used a 229
commercially available ELISA kit from ENZO (Cat- 230
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Fig. 1. Intracerebroventricular treatment with A42 causes a change in tau conformation only in male or ovariectomized female mice.
Representative western blot of brain samples from control (saline) and treated A42 peptides for ICV male and female hTau mice using a
conformational tau antibody (MC1) and a total tau antibody (Tau 5) for detection. Some female mice were subjected to ovariectomy. -actin
served as loading control. Densitometric quantification shows an increase of the total protein level of both MC1 and Tau 5 in male and
ovariectomized female mice injected or not with A42. The data are mean ± standard error of the mean (SEM); *p < 0.05; **p < 0.01 versus
control; §p < 0.05 versus OVX by one-way ANOVA followed by Bonferroni post test n = 5.
MicroRNA isolation and quantitative real time233
PCR234
MicroRNA was isolated from brains of female235
mice using the MagMAXmirVana kit and according236
to manufacturer’s protocol (Applied Biosystems,237
Foster City, CA, USA). Subsequently, cDNA syn-238
thesis was performed using the TaqMan Mi-croRNA239
Reverse Transcription Kit (Applied Biosystems,240
Foster City, CA, USA) and a RT-primer pool con-241
taining microRNA-specific stem-loop primers for 242
miR218 (Mature miRNA Sequence: UUGUGCUU- 243





Each qPCR contained 1.3 L transcribed cDNA, 249
1 L 20X TaqMan MicroRNA Assay and 10 L 250
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Fig. 2. The conformational change mediated by A42 is induced by protein hyperphosphorylation. A) Representative western blot of brain
extracts from control (saline) and treated A42 peptides for ICV male and female hTau mice using antibodies specific for the detection of
pathological tau phosphorylation sites such as AT8, pS422, and pS396. Some female mice were subjected to ovariectomy. actin served as
loading control. Densitometric analysis shows a significant increase of total protein levels of AT8, pS422, and pS396 only in male mice and
ovariectomized female mice. B–D) Representative western blot of brain extracts from control (saline) and treated A42 peptides for ICV
male and female hTau mice using p JNK (B), pERK1/2 (C), and pGSK3 (D). Some female mice were subjected to ovariectomy. -actin
served as loading control. Densitometric analysis shows a significant increase of total protein levels of all the three kinases only in male mice
and ovariectomized female mice. The data are mean ± standard error of the mean (SEM); *p < 0.05; **p < 0.01 versus control; §p < 0.05
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Biosystems) in a total volume of 20.3 L. Each sam-252
ple was processed in doublets for 2 min at 50◦C,253
10 min at 96% and then for 40 cycles of 95◦C for254
15 s and 60◦C for 60 s using the StepOnePlus Real255
Time PCR (Applied Biosystems Foster City, CA,256
USA). The mean Ct-values were technically normal-257
ized using the snRNA-U6, and the expression level258
calculated as 2−Ct (Ct= Ct miR218− Ct snRNA-259
U6andCt= Ct miR218−Ct calibrator).260
Statistical analysis261
Statistical analysis was performed using GraphPad262
Prism version 4.0 (GraphPad software, San Diego).263
All values were presented as mean ± standard error264
of the mean (SEM). Means were compared by one or265
two-way analysis of variance (ANOVA) with Bon-266
ferroni as a post-hoc test. Values of *p < 0.05 were267
considered significant, **p < 0.01 very significant,268
and ***p < 0.001 extremely significant.269
RESULTS270
Intracerebroventricular treatment with Aβ42271
causes a change in tau conformation only in272
male or ovariectomized female mice273
Figure 1 shows that, as previously demonstrated,274
the intracerebroventricular injection of 200 nM A42275
in male hTau mice is able to determine a patholog-276
ical conformational change of the tau protein. The277
same treatment is able to determine this effect only278
in female mice after ovariectomy. The same result279
was obtained by evaluating the total tau protein lev-280
els. As can be seen, treatment with A42 significantly281
increases total tau levels in male (1.5-fold increase)282
and ovariectomized female mice (1.5-fold increase)283
with respect to control female mice injected or not284
with A142.285
The conformational change mediated by Aβ42 is286
induced by protein hyperphosphorylation287
To understand if the conformational change of tau288
was due to hyperphosphorylation, we measured the289
phosphorylation of some specific sites related to the290
pathology by western blotting. Phosphorylation lev-291
els were studied through the use of the AT8 antibody292
(which recognizes the Ser 202/Thr 205 epitopes), the293
antibody S396 and S422. These are all phosphoryla-294
tion sites closely associated with disease progression.295
In Fig. 2A, we show that the treatment with A42 296
induces phosphorylation of the sites taken into con- 297
sideration in male and ovariectomized female mice, 298
while in control females, phosphorylation of the sites 299
is not observed. The increase in phosphorylation 300
is extremely significant for all the phosphoryla- 301
tion sites studied: (+4–5-fold increase AT8; 3–4-fold 302
increase S422; and +4–5-fold increase S396). We 303
previously showed that these sites are phosphory- 304
lated by GSK3, ERK, and JNK kinases [4]. We 305
therefore studied the kinase levels in nuclear lysates. 306
Figure 2B shows that A42 treatment significantly 307
increases pJNK levels in nuclear extracts of male 308
mice (+3-fold increase) or ovariectomized females 309
(+3-fold increase). A similar result was obtained by 310
measuring the nuclear levels of pERK and pGSK3 311
which increase in the same groups by about three 312
times compared to the controls (Fig. 2C, D). 313
Estradiol hormone therapy protects against 314
Aβ42-mediated tau conformational change 315
To confirm that the presence of estrogens is 316
involved in the different effect exerted by the treat- 317
ment with A42 on the pathological conformational 318
change of tau, groups of female mice, ovariectomized 319
or not were subcutaneously treated with estradiol 320
(E2) (1 g/kg) and fed with a soy-free diet for three 321
weeks. We first tested the validity of the treatment by 322
measuring the levels of estradiol in the experimental 323
groups. As can be seen, oophorectomy significantly 324
decreases circulating estradiol levels (–60%), while 325
E2 treatment determines an increase in levels that 326
becomes significantly higher with respect to control 327
females (+100%) (Fig. 3). Figure 4A shows that the 328
treatment with estradiol completely protects both the 329
pathological conformational change and the increase 330
of total tau mediated by A42 in ovariectomized 331
females. Then, to further confirm the protective role 332
of estradiol, we studied the insoluble fraction by 333
sarkosyl detergent technique, and the results showed 334
a tau band at approximately 75 kDa molecular weight 335
revealed with Tau 46 antibody after injection of 336
A42 in ovariectomized female, whereas the therapy 337
with estradiol blocks the aggregation of tau protein 338
(Fig. 4B). 339
Estradiol therapy protects female hTau mice 340
against Aβ42-mediated tau hyperphosphorylation 341
Figure 5 shows that enrichment with estradiol 342
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Fig. 3. Estradiol hormone therapy significantly increases E2 levels.
Groups of female mice, ovariectomized or not, were subcuta-
neously treated with E2 (1 g/kg) and fed with a soy-free diet
for three weeks. To test the validity of the treatment, we mea-
sured E2 levels in serum of our experimental groups. We observed
that the ovariectomy induces a significant decrease in hormone
levels, whereas the treatment protects the decrease of E2 levels,
that significantly increased with respect to controls. The data are
mean ± standard error of the mean (SEM); *p < 0.05; **p < 0.01
versus control by one-way ANOVA followed by Bonferroni post
test n = 6.
mediated phosphorylation, after oophorectomy, of344
pathology-related sites (Fig. 5A). As expected, the345
kinases involved in the phosphorylation of the above346
sites do not appear induced; thus, as observed in347
Fig. 5B, the levels of nuclear pJNK, pERK, and348
pGSK3 are absolutely comparable to the levels of349
the control females.350
Estrogen hormone therapy protects male hTau351
mice against Aβ42-mediated tau conformational352
change and hyperphosphorylation353
To further confirm the protective role of estra-354
diol on the pathological conformational change of355
tau and its hyperphosphorylation, we also treated356
hTau male mice with estradiol, following the same357
protocol as the females. As can be see in Fig. 6,358
the treatment with estradiol is able to completely359
protect both the conformational change of tau as360
revealed by the significant increase of the band361
revealed with MC1 antibody as well as its hyper-362
phosphorylation revealed by using AT8 antibody363
that recognizes Ser202/Thr205 phospho-epitopes364
(Fig. 6).365
Estradiol hormone therapy protects against 366
oxidative stress and downregulate miRNA 218 367
It is well known that E2 treatment, at least dur- 368
ing the early stage of AD pathology, significantly 369
promotes the recovery of cognitive function and 370
upregulated neurogenesis-related mediators in A42 371
mice and that these effects may have been due, at 372
least in part, to decreased levels of oxidative stress 373
via reductions in the production of nitric oxide and 374
reactive oxygen species [12]. Thus, we tested the total 375
antioxidant capacity in our experimental groups. As 376
shown in Fig. 6A, ovariectomy is capable of causing 377
a significant decrease in antioxidant capacity (–50%) 378
and the simultaneous intracerebroventricular injec- 379
tion of A42 induces a further deterioration of the 380
parameter (–70%). Treatment with estradiol protects 381
the drop-in antioxidant capacity by bringing it back 382
to control values (Fig. 6A). 383
Finally, we measured levels of miR218, since 384
recent discoveries demonstrate that estrogen recep- 385
tors are able to modulate the expression of microRNA 386
involved in tau phosphorylation [13]. In particular it 387
has been found that increase of miRNA 218 reduces 388
level of target protein tyrosine phosphatase  with 389
consequent enhancement of tau phosphorylation. 390
We observed that levels of miR218 are significantly 391
higher in ovariectomized female mice, injected or not 392
with A42, whereas the E2 treatment is followed by 393
a total protection of the miRNA increase (Fig. 6B). 394
It is interesting to note that the results obtained on 395
male hTau mice treated with A are similar to those 396
obtained in females after oophorectomy (Fig. 6C, D). 397
DISCUSSION 398
In our work we pursued the hypothesis that gender 399
influences the effect of A42 monomers on pathologi- 400
cal tau conformational change. Our data revealed that 401
A42 produced pathological conformational changes 402
and hyperphosphorylation of tau protein in male 403
or ovariectomized female mice but not in control 404
female. The risk of developing AD as well as its 405
progression and severity are known to be extremely 406
different in men and women [14]. A link between 407
the drop-in estrogen and the pathology is confirmed 408
by data indicating that early menopause increases 409
the risk of developing dementia [5]. Furthermore, 410
cognitive decline is greater in women than in men 411
at the same stage of disease and this is evidently 412
correlated with estrogen levels [15]. The debate on 413
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Fig. 4. Estradiol hormone therapy protects against A42-mediated tau conformational change. A) Representative western blot of brain
samples from control (saline) and treated A42 peptides for ICV female hTau mice using a conformational tau antibody (MC1) and a total
tau antibody (Tau 5) for detection. Some female mice were subjected to ovariectomy and or to E2 (1 g/kg) and soy-free diet for three
weeks. -actin served as loading control. Densitometric quantification shows an increase of the total protein level of both MC1 and Tau 5
in ovariectomized female mice injected or not with A42; the treatment with estradiol completely protects the conformational change and
the increase of tau protein. B) Representative western blot of insoluble tau fraction by sarkosyl detergent technique extracts from control
(saline) and treated A42 peptides for ICV female hTau using Tau 46 antibody for detection. -actin served as loading control. After injection
of A42 in ovariectomized females, we showed a band at approximately 75 kDa molecular weight revealed with Tau 46 antibody, whereas
estradiol blocks the aggregation of tau protein. The data are mean ± standard error of the mean (SEM); *p < 0.05; **p < 0.01 versus control;
§p < 0.05 versus OVX by one-way ANOVA followed by Bonferroni post test n = 5.
active in the last years and recently it has taken new415
life, thus finding new therapeutic approaches for AD416
is one of the most important challenges of modern417
medicine. Numerous experimental evidences have418
shown that estrogens have protective effects on the 419
induction of neuroinflammation and neurodegener- 420
ation [16–18]. The encouraging results obtained in 421
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Fig. 5. Estradiol hormone therapy protects against A42-mediated tau hyperphosphorylation. A) Representative western blot of brain extracts
from control (saline) and treated A42 peptides for ICV female hTau mice using antibodies specific for the detection of pathological tau
phosphorylation sites such as AT8, pS422, and pS396. Some female mice were subjected to ovariectomy and or to E2 (1 g/kg) and soy-free
diet for three weeks. -actin served as loading control. Densitometric analysis shows an increase of total protein levels of AT8, pS422, and
pS396 in ovariectomized female mice injected or not with A42; the treatment with estradiol completely protects the hyperphosphorylation
of tau protein. B–D) Representative western blot of brain extracts from control (saline) and treated A42 peptides for ICV female hTau mice
using p JNK (B), pERK1/2 (C), and pGSK3 (D). Some female mice were subjected to ovariectomy and or to E2 (1 g/kg) and soy-free diet
for three weeks. -actin served as loading control. Densitometric analysis shows an increase of total protein levels of all the three kinases
in ovariectomized female mice injected or not with A42; the treatment with estradiol completely protects the activation of the kinases.
The data are mean ± standard error of the mean (SEM); *p < 0.05; **p < 0.01 versus control; §p < 0.05 versus OVX by one-way ANOVA
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Fig. 6. Estradiol hormone therapy protects male mice against A42-mediated tau conformational change as well as hyperphosphorylation.
Representative western blot of brain samples from control (saline) and treated A42 peptides for ICV male hTau mice using a conformational
tau (MC1) and a specific antibody for tau pathological phosphorylation (AT8) for detection. Some male mice were subjected to E2 (1 g/kg)
and soy-free diet for three weeks. -actin served as loading control. Densitometric quantification shows an increase of the total protein level
of both MC1 and AT8 in mal mice injected or not with A42; the treatment with estradiol completely protects the conformational change and
the increase of tau phosphorylation. The data are mean ± standard error of the mean (SEM); **p < 0.01 versus control by one-way ANOVA
followed by Bonferroni post test n = 5.
clinical trials had shown that the use of replacement423
therapy significantly increased the risk of dementia424
and cognitive decline [19, 20]. These studies sug-425
gested that patients aged 65 and over, already in426
menopause for a long time, did not represent an427
adequate experimental group, because replacement428
therapy is indicated for women who have just gone429
through menopause, and suggested the presence of a430
therapeutic window useful for this type of therapeu-431
tic approach [21]. More recently, emerging evidence432
suggests that protein tau could be a potential target for433
estrogens. It has been demonstrated that 17 estra-434
diol promotes tau dephosphorylation in vitro in rat435
cortical neurons and SH-SY5Y neuronal cells [22].436
Other authors confirmed these results showing that437
E2 prevent the phosphorylation of tau in an estro-438
gen receptor-mediated and dose-dependent manner439
[23]. In vivo studies have shown that estrogenic treat-440
ment increases GSK3 phosphorylation in Ser 9/21,441
a site that inactivates the kinase activity, protecting442
the phosphorylation of pathological sites related to443
disease progression [24]. Moreover, literature data 444
suggest that estrogens exert their protective action 445
through their alpha-type receptor, which interacts 446
with insulin-like growth factor 1 receptor (IGF-R1) 447
by incorporating itself into a macromolecular com- 448
plex that includes phosphoinositol 3 kinase (PI3K) 449
and protein kinase A (AKT). The activation of these 450
signal pathways leads to an inhibition of GSK3 451
and therefore to a reduction in tau phosphoryla- 452
tion [25]. Our results confirm the protective role 453
of estrogens on the pathological conformation and 454
hyperphosphorylation of tau mediated by intracere- 455
broventricular injection with A42 in hTau female 456
mice. From our results, it cannot be determined 457
if estradiol acts as an antioxidant compound and, 458
therefore, in a mode independent of its receptor 459
or modulates at the receptor level protective signal 460
pathways. We showed that it inhibits the kinases 461
that, under A treatment, hyperphosphorylate tau; 462
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Fig. 7. Estradiol hormone therapy protects against oxidative stress and downregulate miRNA 218. A) Evaluation of the total antioxidant
capacity in female mice subjected to ovariectomy and or to E2 (1 g/kg) and soy-free diet for three weeks. We show that ovariectomy
significantly decreases the antioxidant capacity respect to control females, whereas the treatment with estradiol protects the drop-in antioxidant
capacity. B) miRNA 21 levels capacity in female mice subjected to ovariectomy and or to E2 (1 g/kg) and soy-free diet for three weeks.
We show that ovariectomy significantly increases the levels of miRNA 218 with respect to controls female, the treatment with estradiol
completely protects the increase. C) Evaluation of the total antioxidant capacity in male mice treated or not with A42. We show that A42
decreases the antioxidant capacity respect to control males. D) miRNA 21 levels capacity in male mice treated or not with A42. We show that
A42 significantly decreases miRNA level respect to control males. *p < 0.05; **p < 0.01 versus control; §p < 0.05 versus OVX by one-way
ANOVA followed by Bonferroni post test n = 5.
A lot of protective mechanisms relating to estro-465
gens have been described in the literature [26]. Most466
recent studies have revealed that estrogens exert an467
antioxidant action not only by direct chemical neu-468
tralization of reactants, but also by modulating the469
expression of antioxidant enzymes that control levels 470
of biological reducing agents [27]. In our experimen- 471
tal models, we found that the decrease of estrogenic 472
levels was followed by a decrease in the total antiox- 473
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estrogenic therapy in ovariectomized female hTau475
mice. Although it is not clear how oxidative stress476
alters tau phosphorylation and aggregation, it is well477
known that tau phosphorylation is related to the478
balance between kinases and phosphatases activi-479
ties. Thus, oxidative stress may alter this balance in480
favor of the activation of kinases that induces the481
hyperphosphorylation of tau. This statement is in482
agreement with the evidence that the estrogenic drop483
is followed by the activation of stress related kinases,484
as well as JNK and ERK 1/2, while the replacement485
therapy reports the phosphorylated nuclear levels to486
those of control.487
Of note, we found that oxidative stress, together488
with important oxidative stress-related risk factors489
related to AD such as hypoxia, hyperglycemia, and490
hypercholesterolemia, are potential causes of the491
increased BACE1, the crucial enzyme for A pro-492
duction, activity [7].493
Recently emerging evidence suggests that estro-494
gens are involved in regulation of microRNAs in495
many pathological conditions [28]. Rao et al. showed496
that estradiol regulates particular target miRNAs in497
a specific tissue and age manner in ovariectomized498
rats [29]. Furthermore, the deprivation of estrogens499
caused the progressive loss of regulation of the500
miRNA, leading to a lack of regulation even after the501
reintroduction of the estrogens [30]. In our work we502
focused our attention on the miRNA 218, because503
it is implicated in the phosphorylation of tau upon504
estrogen receptor (ER)  and  activation. There are505
two known ERs, usually referred to as ER and ER,506
and both are widely distributed in the brain [31]. In507
the brain of patients with AD, both ER and ER508
are defective. Mitochondrial ER is reduced in the509
frontal cortex of female patients with AD [32], and510
the alternative splicing of ER mRNA is decreased511
in the AD brain especially in female patients [33].512
Moreover, in the hippocampus of AD patients the513
ER-expressing neurons are reduced [34], whereas514
ER immunoreactivity is increased [35]. These find-515
ings indicate a potential role of these two receptors in516
the pathogenesis of AD. Then it has been reported that517
the neuroprotection against A toxicity by estrogens518
requires the expression of both receptors and the acti-519
vation of mitogen-activated protein kinase pathway520
[36]. Specifically, Xiong et al. demonstrated opposite521
effects of these two receptors on tau phosphorylation.522
ER overexpression increased miRNA 218 expres-523
sion and the hyperphosphorylation of tau, whereas524
ER decreased miRNA 218 expression and tau phos-525
phorylation [13]. Interestingly, a number of miRNA526
218 targets multiple components of receptor tyrosine 527
signaling pathways [37]. The increase in miRNA 218 528
downregulates protein tyrosine phosphatase  that 529
promotes tau phosphorylation [13]. This finding is in 530
agreement with our results that demonstrate higher 531
levels of miRNA 218 in ovariectomized female mice 532
in comparison to control females. 533
Our study indicates that factors as age, reproduc- 534
tive stage, hormone levels, and the interplay with 535
other risk factors should be considered in women, in 536
order to identify the best appropriate treatment with 537
estrogens in prevention of cognitive impairment. 538
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Cagnotto A, Rossi A, Morbin M, Di Fede G, Tagliavini F, 579













M. Guglielmotto et al. / Estradiol Protects Aβ42 -Mediated Tau Alteration 13
in amyloid- (A) 1-42 molecular assembly. J Biol Chem581
289, 24143-24152.582
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[25] Hansberg-Pastor V, González-Arenas A, Piña-Medina 643
AG, Camacho-Arroyo I (2015) Sex hormones regulate 644
cytoskeletal proteins involved in brain plasticity. Front Psy- 645
chiatry 6, 165. 646
[26] Vegeto E, Villa A, Della Torre S, Crippa V, Rusmini P, 647
Cristofani R, Galbiati M, Maggi A, Poletti A (2019) The 648
role of sex and sex hormones in neurodegenerative disease. 649
Endocr Rev 41, 273-319. 650
[27] Cervellati C, Bergamini CM (2016) Oxidative damage and 651
the pathogenesis of menopause related disturbances and 652
diseases. Clin Chem Lab Med 54, 739-753. 653
[28] Reddy PH, Tonk S, Kumar S, Vijayan M, Kandimalla 654
R, KuruvaCS, Reddy AP (2017) A critical evaluation 655
of neuroprotective and neurodegenerative MicroRNAs in 656
Alzheimer’s disease. Biochem Biophys Res Commun 483, 657
1156-1165. 658
[29] Rao YS, Mott NN, Wang Y, Chung WC, Pak TR (2013) 659
MicroRNAs in the aging female brain: A putative mecha- 660
nism for age-specific estrogen effects. Endocrinology 154, 661
2795-2806. 662
[30] Rao YS, Shults CL, Pinceti E, Pak TR (2015) Prolonged 663
ovarian hormone deprivation alters the effects of 17- 664
estradiol on microRNA expression in the aged female rat 665
hypothalamus. Oncotarget 6, 36965-36983. 666
[31] Perez SE, Chen EY, Mufson EJ (2003) Distribution of estro- 667
gen receptor alpha and beta immunoreactive profiles in the 668
postnatal rat brain. Brain Res Dev Brain Res 145, 117- 669
139. 670
[32] Long J, He P, Shen Y, Li R (2012) New evidence of mito- 671
chondria dysfunction in the female Alzheimer’s disease 672
brain: Deficiency of estrogen receptor-. J Alzheimers Dis 673
30, 545-558. 674
[33] Ishunina TA, Swaab DF (2012) Decreased alternative splic- 675
ing of estrogen receptor- mRNA in the Alzheimer’s disease 676
brain. Neurobiol Aging 33, 286-296.e283. 677
[34] Hu XY, Qin S, Lu YP, Ravid R, Swaab DF, Zhou JN 678
(2012) Decreased estrogen receptor-alpha expression in hip- 679
pocampal neurons in relation to hyperphosphorylated tau in 680
Alzheimer patients. Acta Neuropathol 106, 213-220. 681
[35] Savaskan E, Olivieri G, Meier F, Ravid R, Muller Spahn F 682
(2001) Hippocampal estrogen beta-receptor immunoreac- 683
tivity is increased in Alzheimer’s disease. Aging Cell 908, 684
113-119. 685
[36] Fitzpatrick JL, Mize CB, Wade CB, Harris JA, Shapiro 686
RA, Dorsa DM (2002) Estrogen-mediated neuroprotection 687
against beta-amyloid toxicity requires expression of estro- 688
gen receptor alpha or beta and activation of the MAPK 689
pathway. J Neurochem 82, 674-682. 690
[37] Mathew LK, Skuli N, Mucaj V, Lee SS, Zinn PO, Sathyan 691
P, Imtiyaz HZ, Zhang Z, Davuluri RV, Rao S, Venneti S, 692
Lal P, Lathia JD, Rich JN, Keith B, Minn AJ, Simon MC 693
(2014) miR-218 opposes a critical RTK-HIF pathway in 694
mesenchymal glioblastoma. Proc Natl Acad Sci U S A 111, 695
291-296. 696
